LivaNova PLC (LIVN) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Devices secteur d'activité. Le siège social de l'entreprise est situé à London, United Kingdom. Le PDG actuel est Vladimir A. Makatsaria.
LIVN a date d'introduction en bourse 2015-10-19, 2,900 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $3.56B.
LivaNova PLC is a global medical device company headquartered in London that designs, develops, manufactures, and sells therapeutic solutions across three primary segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment produces heart-lung machines, oxygenators, and perfusion systems for surgical use, while the Neuromodulation segment markets the VNS Therapy System, an implantable device for treating drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea, and is developing the VITARIA System for heart failure treatment. The Advanced Circulatory Support segment provides temporary life support solutions for cardiopulmonary and respiratory support. LivaNova serves hospitals, medical institutions, and healthcare providers worldwide through a network of direct sales representatives and independent distributors, and collaborates with leading organizations such as Verily on clinical research initiatives.
